Lead Product(s) : mRNA-LNP Based Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : Investments will harness the power of the mRNA-LNP technology and deliver potential new breakthrough vaccines and therapeutics that address significant unmet needs for patients. This agreement expands LNP capabilities and explore more projects within exi...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 01, 2022
Lead Product(s) : mRNA-LNP Based Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Campylobacter Jejuni Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Scandinavian Biopharma
Deal Size : $102.0 million
Deal Type : Collaboration
VaxAlta Inc. Announces License Agreement With Scandinavian Biopharma
Details : Under the terms of the agreement, Scandinavian Biopharma and VaxAlta will jointly be responsible for the development of potential vaccine candidates for C. jejuni for human applications, and Scandinavian will lead the development, registration and commer...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 21, 2021
Lead Product(s) : Campylobacter Jejuni Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Scandinavian Biopharma
Deal Size : $102.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
AbCellera and Lilly to Co-develop Antibody Therapies for COVID-19
Details : AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for COVID-19.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
December 03, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ICON Study confirmed that the use of ivermectin is linked with a lower mortality in hospitalized COVID-19 patients despite being limited to an orally dosed tablet with poor bioavailability, which the company believes would be directly addressed with ...
Product Name : Ivectosol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2020
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voclosporin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aurinia Pharmaceuticals has initiated an open-label exploratory trial to analyse the antiviral effects of voclosporin in kidney transplant recipients (KTRs) with Covid-19. Voclosporin is a novel calcineurin inhibitor (CNI) used for treating patients with...
Product Name : Lupkynis
Product Type : Peptide
Upfront Cash : Inapplicable
October 28, 2020
Lead Product(s) : Voclosporin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Government of Canada
Deal Size : $18.2 million
Deal Type : Funding
Details : PNI will use the investment to advance a best-in-class COVID-19 mRNA vaccine candidate to clinical trials.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 23, 2020
Lead Product(s) : COVID-19 mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Government of Canada
Deal Size : $18.2 million
Deal Type : Funding
Lead Product(s) : Fenretinide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Laurent Pharmaceuticals Joins Battle Against COVID-19
Details : Laurent Pharmaceuticals is planning to test its lead drug LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.
Product Name : LAU-7b
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2020
Lead Product(s) : Fenretinide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Valeo Pharma Files Natural Product License with Health Canada for Bioflavonoid Formulation, Hesperco
Details : Valeo Pharma has filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.
Product Name : HesperCo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Hesperidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : VIDO-InterVac
Deal Size : Undisclosed
Deal Type : Partnership
Dalton, VIDO-InterVac Partner to Develop COVID-19 Vax
Details : Under this Partnership, Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early Phase clinical trials from Dalton`s cGMP biopharmaceutical facility in Toronto, Canada.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : VIDO-InterVac
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Plant Based Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : ZYUS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19
Details : ZYUS will leverage its bio-pharmaceutical plant technology platform and expertise to develop and express a protein that VIDO-InterVac has identified as a potential antigen for a COVID-19 vaccine.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 05, 2020
Lead Product(s) : Plant Based Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : ZYUS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration